Regeneron (REGN) news
Recent news
Bio-pharmaceutical stocks rose in regular trading, with Eli Lilly up 3.9%, Vertex Pharmaceuticals gaining 1.6% and Regeneron Pharmaceuticals rising 2.1%.
AInvest Wire · 14h agoBio-pharmaceutical stocks rose in intraday trading, with Biogen up 3.7%, Regeneron gaining 2.3% and Twist Bioscience rising 3.2%.
Bio-pharmaceutical stocks experienced gains during intraday trading on October 12, 2026, with several key names showing positive momentum. Biogen (BIIB) rose by 3.7%, while Regeneron (REGN) added 2.3% and Twist Bioscience (TWST) climbed 3.2%. The sector’s performance reflects ongoing investor…
AInvest Wire · 2d agoRegeneron's Pasatru cuts flare-ups vs placebo through wk 84
A clinical trial evaluating Regeneron’s Pasatru has demonstrated a reduction in flare-ups compared to a placebo over an 84-week period. The findings suggest that the treatment may offer sustained benefits for patients experiencing recurrent inflammatory episodes. The study, which monitored…
AInvest Wire · 2d agoRegeneron Pharmaceuticals - Pasatru shows sustained efficacy and consistent safety profile from weeks 56 to 84
Regeneron Pharmaceuticals has reported sustained efficacy and a consistent safety profile for its investigational therapy, Pasatru, in clinical data from weeks 56 to 84 of an ongoing trial. The findings indicate that the treatment continues to demonstrate effectiveness over an extended period, with…
AInvest Wire · 2d agoRegeneron's Pasatru shows zero new bone lesions at 84 wks
Regeneron Pharmaceuticals, Inc. has reported that its investigational therapy, Pasitru, demonstrated zero new bone lesions in clinical trials after 84 weeks of treatment. This outcome is significant for patients with conditions involving bone degradation or metastasis, where the prevention of new…
AInvest Wire · 2d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.